Therapeutic Respiratory Devices Market By Product Type (Positive Airway Pressure Devices, PAP Masks & Accessories, Oxygen Therapy Equipment, Mechanical Ventilators, Non-Invasive Ventilation & Respiratory Assist Devices, High-Flow Therapy & Humidification Systems, Nebulizers & Inhalation Devices, Airway-Clearance Devices, Respiratory Consumables & Accessories); By Application (Sleep Apnea, Chronic Obstructive Pulmonary Disease, Asthma, Chronic Respiratory Failure, Acute Respiratory Failure & ICU Care, Neonatal Respiratory Support, Bronchiectasis & Secretion Management, Other Respiratory Disorders); By End User (Hospitals, Home Healthcare & Durable Medical Equipment Providers, Sleep Clinics & Specialty Respiratory Clinics, Ambulatory Care Centers, Long-Term Care Facilities); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Therapeutic Respiratory Devices Market: Connected PAP Systems, Home Ventilation Coverage, and Consumable-Led Hospital Demand Reshape Competition

The Global Therapeutic Respiratory Devices Market was valued at USD 14.56 billion in 2025 and is projected to reach USD 23.75 billion by 2032, growing at a CAGR of 7.25% during the forecast period, according to Strategic Market Research.

 

The Therapeutic Respiratory Devices Market includes positive airway pressure systems, oxygen concentrators, mechanical and non-invasive ventilators, nebulizers, inhalation devices, humidification systems, and airway-clearance equipment. Each category follows a different treatment, reimbursement, and replacement pathway.

 

PAP manufacturers depend on diagnosed sleep apnea, therapy acceptance, adherence, and regular mask replacement. Oxygen suppliers serve patients who meet clinical hypoxemia criteria rather than the wider population reporting breathlessness. Ventilator demand follows ICU admissions, chronic respiratory failure, and hospital capacity. Inhaler and nebulizer use is tied to drug prescriptions, technique, and patient ability to operate the device correctly.

 

Recurring accessories and consumables account for a growing share of supplier revenue. PAP masks, cushions, filters, breathing circuits, humidifier chambers, oxygen cannulas, nebulizer kits, and airway-clearance accessories require regular replacement. ResMed’s March 2026 quarter illustrates the revenue structure: sleep and breathing devices generated USD 735.7 million, while masks and other products contributed USD 524.8 million and grew 15% year over year.

 

Respiratory Disease Burden Creates Several Separate Device Markets

Obstructive sleep apnea provides the largest potential population for PAP therapy. A global modelling study estimated that 936 million adults aged 30–69 had mild-to-severe OSA, including 425 million with moderate-to-severe disease. Diagnosis rates, sleep-testing access, treatment acceptance, insurance requirements, and adherence reduce the number who become regular PAP users.

The United States had an estimated 83.7 million adults with OSA in 2024, including 30% with moderate disease and 18% with severe disease. Moderate-to-severe patients represent the more actionable treatment group, although symptom burden, cardiovascular risk, clinician referral, and payer qualification continue to influence prescription rates.

COPD supports demand across oxygen therapy, nebulization, non-invasive ventilation, airway clearance, and hospital mechanical ventilation. The disease caused 3.4 million deaths in 2023, accounting for approximately 6% of global mortality. U.S. age-adjusted diagnosed COPD prevalence reached 3.8% in 2023, while 141,733 deaths were recorded during the year.

More than 1.5 million people in the United States have been prescribed long-term oxygen therapy. This treated population provides a direct demand base for stationary and portable concentrators, cannulas, tubing, servicing, replacement equipment, and durable medical equipment contracts.

Asthma creates the widest inhalation-device population. WHO estimated that 363 million people had asthma in 2023, with approximately 442,000 deaths. Metered-dose inhalers, dry-powder inhalers, soft-mist devices, spacers, and nebulizers remain central to drug delivery, although the device market is closely tied to pharmaceutical prescriptions and patient technique.

Mechanical ventilation demand is concentrated in high-acuity care. The Society of Critical Care Medicine reports that approximately 20%–40% of U.S. ICU admissions require mechanical ventilation. Hospital purchasing therefore follows ICU capacity, sepsis, respiratory failure, trauma, surgery, neonatal care, emergency preparedness, and replacement of aging installed systems.

 

Therapeutic Respiratory Devices Market Segment Analysis

PAP Devices Generate Long-Term Accessory and Monitoring Revenue

CPAP and auto-adjusting PAP systems form one of the largest chronic homecare segments. Initial equipment placement is followed by repeat purchases of masks, cushions, headgear, tubing, filters, and humidifier components.

Bilevel devices serve patients who require separate inspiratory and expiratory pressure settings, including selected people with OSA, chronic hypoventilation, neuromuscular disease, or respiratory failure. ResMed’s AirCurve 11 expanded connected monitoring into bilevel therapy in 2024, allowing clinicians and homecare providers to track use, leakage, pressure, and therapy response through digital platforms.

Mask performance can determine whether the patient remains on treatment. Leakage, skin pressure, dryness, claustrophobia, noise, and poor fit frequently cause discontinuation even when the PAP machine functions correctly.

A 2025 study of 1,907 patients found that 45% achieved high long-term CPAP adherence, 39% were non-adherent, and 16% recorded low adherence. Patients who achieved strong adherence during the first month had a 79% probability of remaining highly adherent after two years. Early mask fitting, humidification, pressure comfort, patient education, and remote troubleshooting directly influence both treatment persistence and recurring accessory sales.

Medicare documentation requirements add another commercial constraint. The 2024 PAP improper-payment rate reached 12.5%, representing an estimated USD 146.1 million in improper payments. Insufficient documentation accounted for 71.2% of the errors. Durable medical equipment suppliers therefore need reliable usage records, physician documentation, delivery confirmation, and continued-use evidence to protect reimbursement.

 

Oxygen Equipment Retains a Large Installed Base but Limited Pricing Power

Home oxygen includes stationary concentrators, portable oxygen concentrators, cylinders, liquid oxygen equipment, conserving devices, regulators, cannulas, and service contracts. Stationary systems support continuous home use, while portable units compete on weight, battery life, oxygen output, noise, durability, and travel convenience.

Clinical qualification restricts demand to patients with documented oxygen need. The Long-Term Oxygen Treatment Trial found no broad survival or hospitalization benefit among most patients with stable COPD and moderate desaturation. Oxygen suppliers cannot treat the entire COPD population as a device opportunity.

Medicare defines a five-year reasonable useful lifetime for oxygen equipment. Homecare providers remain responsible for maintenance and service continuity throughout the covered period, making reliability, repair cost, fleet management, and replacement logistics important purchasing considerations.

Portable concentrators retain stronger product differentiation than basic stationary hardware. Inogen’s Rove 6 provides six pulse-dose settings for ambulatory patients, while the Voxi 5 expands the company into stationary continuous-flow oxygen. The broader portfolio allows Inogen to serve both mobile and home-based users through one supplier relationship.

Reimbursement pressure remains substantial. Competitive bidding and historical fee reductions have limited pricing across mature oxygen categories. Suppliers defend margins through direct-to-consumer channels, international sales, low service requirements, battery performance, and broader product portfolios rather than concentrator hardware alone.

 

Hospital Ventilation and High-Flow Therapy Support Premium Equipment Sales

Mechanical ventilators remain among the highest-value respiratory devices because they support life-sustaining treatment in ICUs, emergency departments, neonatal units, transport settings, and long-term acute-care facilities.

Hospital buyers compare ventilation modes, patient-range coverage, alarm performance, battery backup, infection-control design, monitoring, interoperability, staff familiarity, consumable availability, service response, and training. Price remains relevant, but clinical reliability and installed-base support carry greater weight in life-support equipment.

High-flow nasal therapy and heated humidification occupy a growing position between conventional oxygen and invasive ventilation. Fisher & Paykel Healthcare’s Airvo 3 delivers high-flow therapy, while the F&P 950 provides heated humidification for invasive and non-invasive respiratory circuits.

Fisher & Paykel Healthcare reported NZD 1.51 billion in hospital-product revenue for FY2026, an 18% increase. New-application hospital consumables grew 16% in constant currency. Airvo 3 and the F&P 950 supported hardware growth, while proprietary circuits, chambers, interfaces, and cannulas generated recurring revenue after installation.

Home non-invasive ventilation gained a clearer U.S. reimbursement pathway in June 2025 when CMS established national coverage criteria for respiratory assist devices and home mechanical ventilators used in chronic respiratory failure caused by COPD. National criteria reduce regional variation, although patients must still meet clinical and continued-use requirements.

The HOT-HMV trial supports targeted home NIV use. At 12 months, the risk of readmission or death was 63.4% among patients receiving home oxygen plus non-invasive ventilation, compared with 80.4% among those receiving oxygen alone. The study involved patients with persistent hypercapnia after a COPD exacerbation and should not be extended to the broader COPD population.

 

Inhalers Reach the Largest Patient Population but Remain Technique-Dependent

Pressurized metered-dose inhalers, dry-powder inhalers, soft-mist inhalers, spacers, and nebulizers serve asthma and COPD patients across primary care, specialist clinics, emergency departments, and home settings.

Patient technique determines how much medication reaches the lungs. A systematic review found that 86.8% of asthma or COPD patients made at least one metered-dose inhaler error, while 45.6% made a critical error capable of materially reducing drug delivery.

Poor adherence also carries measurable clinical consequences. A 2024 meta-analysis linked poor adherence to inhaled COPD medication with a 40% higher risk of exacerbation. Dose counters, breath actuation, simplified preparation, connected sensors, reminder functions, and patient training can therefore improve both clinical performance and product differentiation.

Nebulizers remain relevant for young children, older adults, severe exacerbations, patients with poor inhaler coordination, and medicines formulated specifically for nebulization. The hardware is mature and price-sensitive, leaving treatment time, portability, noise, cleaning, aerosol performance, and ease of use as the main areas of differentiation.

 

Airway-Clearance Devices Expand Beyond Traditional Vest Therapy

Airway-clearance devices serve patients with bronchiectasis, cystic fibrosis, primary ciliary dyskinesia, COPD, and selected neuromuscular conditions. Available technologies include oscillatory positive expiratory pressure, mechanical insufflation-exsufflation, high-frequency chest-wall oscillation, and intrapulmonary percussive systems.

The European Respiratory Society issued a strong recommendation in 2025 for airway-clearance techniques in most patients with bronchiectasis. Device selection remains individualized, but the guideline gives pulmonologists and respiratory physiotherapists a stronger basis for structured home treatment.

Inogen received FDA clearance for SIMEOX 200 in December 2024. The system applies oscillatory negative pressure during exhalation to mobilize bronchial secretions and is intended for patients capable of producing an independent cough. The product gives Inogen a route beyond oxygen equipment into a higher-growth respiratory specialty.

Synchrony Medical received FDA clearance for LibAirty during the same month. LibAirty combines a powered vest, control unit, and connected application for hospital, clinic, and home use. Post-clearance studies will need to demonstrate adherence, reduced exacerbations, and lower treatment burden before the product can secure broad reimbursement.

 

ResMed Strengthens PAP Leadership Through Software and Mask Replacement

ResMed’s competitive position rests on the connection between AirSense and AirCurve devices, AirView clinical monitoring, the myAir patient application, and a broad mask portfolio.

Smart Comfort received FDA clearance in December 2025 as a digital medical device that recommends personalized AirSense 11 comfort settings. The software uses real-world sleep-therapy data to guide pressure-ramp and expiratory-comfort settings during the early treatment period.

Early comfort matters commercially because patients who abandon CPAP stop generating mask, cushion, filter, and tubing replacements. ResMed’s software investment protects both clinical adherence and recurring accessory revenue.

The company reported USD 1.26 billion in Sleep and Breathing Health revenue in the March 2026 quarter. Masks and other products grew faster than devices, confirming that installed-base replenishment remains one of the strongest revenue streams in the PAP market.

 

Fisher & Paykel Healthcare Combines Hospital Systems with Recurring Interfaces

Fisher & Paykel Healthcare serves invasive ventilation, non-invasive ventilation, high-flow therapy, heated humidification, anaesthesia, home respiratory support, and OSA masks.

FY2026 revenue reached NZD 2.31 billion. Hospital products contributed NZD 1.51 billion, while homecare revenue reached NZD 802.7 million. The portfolio gives the company exposure to acute-care equipment, hospital consumables, flow generators, humidification circuits, cannulas, and homecare mask replacement.

Nova Nasal, launched in selected markets in 2025, extends the company’s interface portfolio. Mask development remains commercially important because comfort and leakage influence adherence, while regular replacement supports recurring revenue.

 

Inogen Broadens Its Portfolio Beyond Portable Oxygen

Inogen generated USD 348.7 million in revenue during 2025, up 3.9%. International portable-oxygen sales increased 18.4%, while weaker U.S. sales and rentals limited overall growth.

Rove concentrators remain the company’s primary mobility products. Voxi 5 adds stationary continuous-flow oxygen, Aurora masks provide an entry into sleep therapy, and SIMEOX 200 moves the company into airway clearance.

The limited U.S. launch of SIMEOX began in 2026 alongside reimbursement-focused evidence generation. Pulmonologist interest alone will not create broad adoption unless Inogen can demonstrate sustained home use, reduced exacerbations, and a workable payment pathway.

The 2025 distribution and development agreement with Yuwell expands Inogen’s stationary oxygen portfolio and strengthens access to China. The partnership also reduces reliance on a single product category and geographic market.

 

ZOLL Expands Its Ventilator Portfolio Through Vyaire Assets

ZOLL acquired selected Vyaire ventilator product lines in October 2024 after Vyaire entered Chapter 11 proceedings. The acquired portfolio includes bellavista, fabian, LTV, and 3100 high-frequency oscillatory ventilators.

The transaction gives ZOLL products covering adult, paediatric, neonatal, transport, invasive, non-invasive, and high-frequency ventilation. Consumables, accessories, service parts, and installed-base support add recurring revenue beyond equipment sales.

Hospitals using former Vyaire systems will judge ZOLL on service continuity, spare-parts availability, software maintenance, and clinical support. Acquisition value depends on retaining those customers rather than only owning the product names.

 

React Health Competes Through Integrated Home Respiratory Support

React Health’s V-Series and VOCSN-derived systems combine ventilation with additional respiratory functions. The V+C configuration integrates ventilation and cough therapy under HCPCS code E0468, giving homecare providers a reimbursement route for patients who require more than one respiratory-support function.

Software version 5.06, released in July 2025, added standby mode and simplified pre-use testing. Software upgrades allow React Health to improve installed systems without replacing the full platform.

A May 2026 removal of affected V+Pro ventilators exposed the risk attached to manufacturing and quality controls. A testing deviation could have allowed undetected oxygen leakage and out-of-specification oxygen delivery. Buyers of life-support equipment will continue to scrutinize factory testing, complaint handling, service responsiveness, and corrective-action processes.

 

Philips Respironics Remains Constrained by Recall Remediation

Philips Respironics continues to manage the consequences of the recall affecting approximately 15 million CPAP, bilevel, and ventilator devices worldwide.

A federal court entered a consent decree in April 2024 requiring remediation and regulatory-compliance actions. Restrictions on aspects of U.S. manufacturing and sales have reduced Philips’ competitive flexibility and redirected prescriptions toward ResMed, Fisher & Paykel Healthcare, React Health, and other suppliers.

The recall raised industry-wide expectations for material selection, complaint handling, software configuration, post-market surveillance, replacement logistics, and patient communication. Respiratory-device buyers now evaluate supplier quality systems alongside performance and price.

 

North America Leads Through Reimbursement and Homecare Infrastructure

North America combines a large diagnosed respiratory population, extensive sleep-testing infrastructure, established durable medical equipment channels, private insurance, Medicare coverage, and advanced hospital respiratory care.

The United States remains the largest commercial PAP market, supported by home sleep testing, cloud-connected devices, replacement schedules, and national DME networks. Strict documentation and adherence requirements also create administrative costs and reimbursement risk.

CMS’s 2025 national home-ventilation criteria give suppliers a clearer route to eligible COPD patients with chronic respiratory failure. Ventilator manufacturers, pulmonologists, hospitals, and homecare providers can now work from a common national framework rather than differing local interpretations.

 

Europe Combines Public Funding with Tender Pressure

The WHO European Region had 81.7 million people living with chronic respiratory disease in 2021, including 6.8 million newly diagnosed patients.

Public health systems fund PAP, oxygen, ventilation, and hospital respiratory care, but national reimbursement rules and tenders vary considerably. Large procurement programs support access while strengthening buyer negotiation on equipment, consumables, service, and replacement costs.

The United Kingdom funds recommended CPAP treatment through NHS pathways when patients meet clinical criteria. Home NIV use is concentrated in defined respiratory-failure populations, while oxygen prescribing remains tied to documented clinical need.

 

Asia Holds the Largest Untreated PAP Population

China has an estimated 176 million adults with OSA, including approximately 66 million with moderate-to-severe disease. India has an estimated 104 million working-age adults with OSA, including 47 million with moderate-to-severe disease.

Sleep-testing capacity, clinician awareness, out-of-pocket payment, local manufacturing, online sales, and distributor reach determine how much of this population converts into PAP use. High modeled prevalence alone does not indicate an equivalent installed-device base.

Japan has a mature home-oxygen market with a changing indication mix. COPD accounted for 37% of surveyed long-term oxygen users during 2021–2023, while pulmonary fibrosis and interstitial pneumonia accounted for 30.1%. Oxygen suppliers increasingly need products suited to fibrotic lung disease, ambulatory use, and emergency power planning.

 

Market Outlook

PAP suppliers will compete through mask comfort, digital onboarding, adherence management, cloud connectivity, and replacement logistics. Pressure delivery has become standardized across established manufacturers, leaving patient persistence and service execution as the main sources of differentiation.

Oxygen equipment will retain a large installed base but remain exposed to reimbursement compression. Portable systems can defend pricing through battery performance, low weight, mobility, direct-to-consumer distribution, and reduced servicing.

Hospital ventilation, high-flow therapy, and humidification will continue to support premium equipment and recurring consumable demand. Home ventilation now has a clearer U.S. reimbursement route for selected COPD patients with chronic respiratory failure.

Airway-clearance equipment is developing into a more credible specialty segment after recent FDA clearances and stronger bronchiectasis guidance. Broad adoption will depend on evidence showing fewer exacerbations, better adherence, and lower homecare burden.

ResMed remains strongest in connected PAP and mask replenishment. Fisher & Paykel Healthcare combines hospital high-flow and humidification with homecare interfaces. Inogen is expanding from portable oxygen into stationary equipment, PAP masks, and airway clearance. ZOLL has widened its ventilator portfolio through Vyaire’s former assets, while React Health, Dräger, and Hamilton Medical compete through integrated functions, clinical workflow, and service support.

Diagnosis, treatment eligibility, reimbursement, adherence, and supplier execution determine device revenue more accurately than respiratory disease prevalence alone.

 

Therapeutic Respiratory Devices Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 14.56 Billion
Revenue Forecast in 2032	USD 23.75 Billion
Overall Growth Rate	CAGR of 7.25% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Application, By End User, By Geography
By Product Type	Positive Airway Pressure Devices, PAP Masks & Accessories, Oxygen Therapy Equipment, Mechanical Ventilators, Non-Invasive Ventilation & Respiratory Assist Devices, High-Flow Therapy & Humidification Systems, Nebulizers & Inhalation Devices, Airway-Clearance Devices, Respiratory Consumables & Accessories
By Application	Sleep Apnea, Chronic Obstructive Pulmonary Disease, Asthma, Chronic Respiratory Failure, Acute Respiratory Failure & ICU Care, Neonatal Respiratory Support, Bronchiectasis & Secretion Management, Other Respiratory Disorders
By End User	Hospitals, Home Healthcare & Durable Medical Equipment Providers, Sleep Clinics & Specialty Respiratory Clinics, Ambulatory Care Centers, Long-Term Care Facilities
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Market Drivers	Rising respiratory disease burden Expansion of home-based respiratory care Increasing adoption of connected PAP systems
Customization Option	Available upon request